Literature DB >> 3607747

Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.

M M Gottardis, V C Jordan.   

Abstract

We have compared the antitumor activities of the antiestrogens, keoxifene (LY 156758) and tamoxifen (TAM), using the N-nitrosomethylurea (NMU) rat mammary carcinoma model. To establish an effective antitumor dose of TAM in this model, rats were treated 2 wk after initiation with NMU for 8 wk with s.c. daily injections of 6.25 micrograms, 25 micrograms, or 100 micrograms of TAM in peanut oil. At the 25-micrograms and 100-micrograms daily doses, TAM completely inhibited tumor appearance during the therapy period. An effective antitumor dose of TAM (100 micrograms daily) was compared to 20-, 100-, or 500-micrograms daily doses of keoxifene 7 wk after NMU initiation. None of the keoxifene-treated groups prevented the appearance of tumors as effectively as TAM during 13 wk of therapy. When keoxifene was compared to TAM at equivalent daily doses of 100 and 500 micrograms daily starting 2 wk after NMU injection, the keoxifene groups again failed to prevent the appearance of all tumors during 10 wk of therapy. TAM, however, completely suppressed any tumor formation. In the same experiment, animals treated with 500 micrograms of TAM had therapy stopped after 10 wk, and tumors started to appear 6 wk later. No tumors appeared when animals (n = 25) were treated continuously for 23 wk with 100 micrograms of TAM. In separate experiments, keoxifene (500 micrograms daily) and TAM (500 micrograms and 100 micrograms daily) administered for 1 wk blocked the binding of [3H]-estradiol in NMU tumors and in uteri. The effect lasted for up to 5 wk after antiestrogen therapy was stopped. These experiments demonstrate that keoxifene is not as effective in its antitumor action as TAM in the NMU model.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3607747

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  65 in total

1.  Raloxifene as a multifunctional medicine? Current trials will show whether it is effective in both osteoporosis and breast cancer.

Authors:  V C Jordan; M Morrow
Journal:  BMJ       Date:  1999-08-07

Review 2.  Breast cancer therapies in development. A review of their pharmacology and clinical potential.

Authors:  D de Valeriola; A Awada; J A Roy; A Di Leo; L Biganzoli; M Piccart
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 3.  Hormone-induced protection against breast cancer.

Authors:  Lakshmi Sivaraman; Daniel Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-01       Impact factor: 2.673

Review 4.  Selective estrogen receptor modulators.

Authors:  Henry U Bryant
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

5.  Beyond raloxifene for the prevention of osteoporosis and breast cancer.

Authors:  V C Jordan
Journal:  Br J Pharmacol       Date:  2006-11-20       Impact factor: 8.739

Review 6.  The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens.

Authors:  D A Tonetti; V C Jordan
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

7.  Disease Subtype-Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A.

Authors:  Suman K Samanta; Anuradha Sehrawat; Su-Hyeong Kim; Eun-Ryeong Hahm; Yongli Shuai; Ruchi Roy; Subrata K Pore; Krishna B Singh; Susan M Christner; Jan H Beumer; Nancy E Davidson; Shivendra V Singh
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

Review 8.  N-Methyl-N-nitrosourea as a mammary carcinogenic agent.

Authors:  Ana I Faustino-Rocha; Rita Ferreira; Paula A Oliveira; Adelina Gama; Mário Ginja
Journal:  Tumour Biol       Date:  2015-09-19

Review 9.  Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients.

Authors:  V Craig Jordan; Joan Lewis-Wambi; Helen Kim; Heather Cunliffe; Eric Ariazi; Catherine G N Sharma; Heather A Shupp; Ramona Swaby
Journal:  Breast       Date:  2007-08-24       Impact factor: 4.380

10.  Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis.

Authors:  Ronald A Lubet; Eva Szabo; Kenneth K Iwata; Stanley C Gill; Chris Tucker; Ann Bode; Vernon E Steele; M Margaret Juliana; Holly L Nicastro; Clinton J Grubbs
Journal:  Cancer Prev Res (Phila)       Date:  2013-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.